Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Followed by Response-Based Reduced Radiation Therapy for CNS Germinomas
NCT06368817Phase 2Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Oct 2024
- Primary completion
- Nov 2033
- Modality
- DNA Intercalators/Alkylators
- Countries
- 3
01
Overview
Phase 2, open-label trial of carboplatin and etoposide in germinoma (7 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free survival at 3 years. Started Oct 2024; status: recruiting.
02
Drugs
carboplatinetoposide
03
Conditions
germinoma
Beyond the preview
Go deeper on NCT06368817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368817.